Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 275

The DOI matches its Crossref record; 114 of the 114 references it cites were found in a registry or an index.

Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery

Open access
Barros, T P, Alderton, W K, Reynolds, H M, Roach, A G, Berghmans, S·2008·British Journal of Pharmacology

Abstract

The zebrafish is a well‐established model organism used in developmental biology. In the last decade, this technology has been extended to the generation of high‐value knowledge on safety risks of novel drugs. Indeed, the larval zebrafish appear to combine advantages of whole organism phenotypic assays and those (rapid production of results with minimal resource engagement) of in vitro high‐throughput screening techniques. Thus, if appropriately evaluated, it can offer undeniable advantages in drug discovery for identification of target and off‐target effects. Here, we review some applications of zebrafish to identify potential safety liabilities, particularly before lead/candidate selection. For instance, zebrafish cardiovascular system can be used to reveal decreases in heart rate and atrial–ventricular dissociation, which may signal human ether‐a‐go‐go‐related gene (h ERG) channel blockade. Another main area of interest is the CNS, where zebrafish behavioural assays have been and are further being developed into screening platforms for assessment of locomotor activity, convulsant and proconvulsant liability, cognitive impairment, drug dependence potential and impaired visual and auditory functions. Zebrafish also offer interesting possibilities for evaluating effects on bone density and gastrointestinal function. Furthermore, available knowledge of the renal system in larval zebrafish can allow identification of potential safety issues of drug candidates on this often neglected area in early development platforms. Although additional validation is certainly needed, the zebrafish is emerging as a versatile in vivo animal model to identify off‐target effects that need investigation and further clarification early in the drug discovery process to reduce the current, high degree of attrition in development. British Journal of Pharmacology (2008) 154, 1400–1413; doi:10.1038/bjp.2008.249; published online 16 June 2008

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjp.2008.249

Cites

114 of 114 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 114 references

Cited by

See all 275

Metadata

Authors
Barros, T. P., Alderton, W. K., Reynolds, H. M., Roach, A. G., & Berghmans, S.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2008-08
Volume
154
Issue
7
Pages
1400-1413
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2006424018
Cited by
275
References
114
FWCI
7.49
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. https://app.cochat.ai/papers/10.1038/bjp.2008.249
The paper
Barros, T. P., Alderton, W. K., Reynolds, H. M., Roach, A. G., & Berghmans, S. (2008). Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery. British Journal of Pharmacology. https://doi.org/10.1038/bjp.2008.249

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.